PeptideScanner
U.S. label record↗Endocrine↗

Lanreotide↗

Related names in cited records: Lanreotide acetate↗

A somatostatin analogue. This profile cites a U.S. label record.↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change. 1

This version supersedes public version 1.

Start here

The evidence at a glance

What is its status in the cited records?

U.S. label record. The cited DailyMed label identifies Lanreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Three selected reports address lanreotide in neuroendocrine tumors and acromegaly. The CLARINET extension follows participants from the original trial and is not an independent randomized experiment.↗↗↗

What the reviewed sources report

CLARINET found longer progression-free survival, without a demonstrated overall-survival or quality-of-life difference. The acromegaly study reported tumor and hormone changes but did not reject its prespecified primary null hypothesis.↗↗↗

What remains unresolved?

  • How do formulation, indication and prior-treatment differences affect applicability?↗↗↗
  • What do complete trial reports and current labels add about harms and longer follow-up?↗↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Lanreotide acetate injection · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The cited label covers specified acromegaly, gastroenteropancreatic neuroendocrine tumor and carcinoid-syndrome settings. Indications and outcomes differ across those populations. Label: 1 ↗

Which safety limits matter?

Warnings include gallstones and complications, altered glucose control, reduced heart rate, thyroid abnormalities, and fat malabsorption or steatorrhea. These label risks are distinct from event rates in an individual trial. Label: 1, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

Lanreotide acetate injection · SPL version 3 · published 2025-06-02

Label ZIP SHA-256: 549b28079c4ff34c485706fc6353164f8e1903e90a1ec7f10f97482b441b0bfe. Extracted XML SHA-256: c8c3f515d19dbbec43ebb5353991467b8f96123d3e513e3e183fd915087f874b.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

The tumor study measured progression-free survival

FDA’s December 2014 review describes a 204-participant, randomized, double-blind placebo-controlled trial in unresectable or metastatic, well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors. The primary endpoint combined radiological progression or death. FDA PDF pp. 32, 36 ↗

More findings, study links and document coverage

Delayed progression did not establish longer survival

FDA found longer progression-free survival with lanreotide. Overall-survival data were immature with no apparent difference between groups at that assessment, so these outcomes should not be treated as interchangeable. FDA PDF pp. 32 ↗

Most participants had stable disease before entry

Nearly all participants had stable disease before randomization. That population limits extrapolation of the result to every rapidly progressing tumor or tumor subtype. FDA PDF pp. 32 ↗

The safety account is indication-specific

The reviewed tumor study reported glucose abnormalities, bradycardia and gallbladder findings. Its exposure and population differ from the earlier acromegaly program; this supplement is not a complete review of every lanreotide use. FDA PDF pp. 40 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

  • Somatuline Depot: FDA selected application review ↗

    Selected sections reviewed · fda-lanreotide-review-2014 · Document/feed date: 2014-12-16

    Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.

    Verified: Somatuline Depot · NDA 022074 · Document dated 2014-12-16. Identity checked on PDF pp. 31.

    Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.

    Retrieved 2026-09-19. Read PDF pages: 31, 32, 36, 40 of 199. SHA-256: 1130ab9cde9c9010cc5f49111f51bac7d096d273aef7696d05817de03fbd0a93.

Remaining work

  • Review the original acromegaly and later carcinoid-syndrome assessments separately.
  • Appraise CLARINET extension and survival follow-up, preserving crossover and enrollment limitations.

Open versioned document coverage and study pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Identity/name search without publication-type filtering; primary human reports, extensions, combinations and other reports require separate eligibility decisions. Known selected reports were recovered.

1259 retrieved · 3 included · 0 excluded · 1256 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"lanreotide"[Title/Abstract] OR "Somatuline"[Title/Abstract]

  • Full-text appraisal and screening of unassessed records remain open.
  • Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.

Showing 25 of 1259 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 33052555 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT00353496.
  2. PubMed 25014687 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT00353496.
  3. PubMed 24423301 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT00690898.
  4. PubMed 42721062 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  5. PubMed 42642161 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  6. PubMed 42703492 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  7. PubMed 42675372 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  8. PubMed 42723843 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  9. PubMed 42729617 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  10. PubMed 42621460 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  11. PubMed 42206253 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  12. PubMed 42053775 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  13. PubMed 42597314 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  14. PubMed 42476150 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  15. PubMed 42442850 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  16. PubMed 42319153 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  17. PubMed 41308086 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  18. PubMed 42365543 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  19. PubMed 42359578 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  20. PubMed 42320793 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  21. PubMed 42030411 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  22. PubMed 41965092 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  23. PubMed 42395255 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  24. PubMed 41964795 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  25. PubMed 41948193 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

3 retrieved · 3 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"LANREOTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:17.646636+00:00 · HTTP 200 · SHA-256 6d38b151d3afa503018c40627791da17e043f4509fc8931e9362836ac2c4224f.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 3 of 3 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA NDA022074 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LANREOTIDE ACETATE.
  2. FDA ANDA217193 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LANREOTIDE ACETATE.
  3. FDA NDA215395 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LANREOTIDE ACETATE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Lanreotide", "Lanreotide acetate"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

    10 retrieved · 0 included · 0 excluded · 10 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Lanreotide", "Lanreotide acetate"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 10 of 10 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. EMA 25634 — not screened: Title-name match awaiting identity and document review. Lanreotide: List of nationally authorised medicinal products - PSUSA/00001826/201705
    2. EMA 36352 — not screened: Title-name match awaiting identity and document review. EU/3/15/1514: Public summary of opinion on orphan designation: Lanreotide acetate for the treatment of autosomal dominant polycystic kidney disease
    3. EMA 51091 — not screened: Title-name match awaiting identity and document review. Lanreotide: List of nationally authorised medicinal products - PSUSA/00001826/202005
    4. EMA 53723 — not screened: Title-name match awaiting identity and document review. Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202105
    5. EMA 56988 — not screened: Title-name match awaiting identity and document review. Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg productspecific bioequivalence guidance
    6. EMA 56989 — not screened: Title-name match awaiting identity and document review. Overview of comments on 'Draft lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product specific bioequivalence guidance'
    7. EMA 57366 — not screened: Title-name match awaiting identity and document review. Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202205
    8. EMA 54970 — not screened: Title-name match awaiting identity and document review. Draft lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product specific bioequivalence guidance
    9. EMA 62726 — not screened: Title-name match awaiting identity and document review. Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202305
    10. EMA 6785 — not screened: Title-name match awaiting identity and document review. P/0302/2013: EMA decision of of 29 November 2013 on the granting of a product-specific waiver for lanreotide (acetate) (Somatuline LA and associated names) (EMEA-001503-PIP01-13)

    EMA search

    Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

    1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Lanreotide", "Lanreotide acetate"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. EMA EU/3/15/1514 — include: EMA orphan feed identifies Lanreotide acetate; designation status: Positive. Orphan designation is not marketing authorization.

    ClinicalTrials.gov search

    ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

    124 retrieved · 0 included · 0 excluded · 124 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    "Lanreotide" OR "Lanreotide acetate"

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:16.840936+00:00 · HTTP 200 · SHA-256 e2f792259e06d2fa9bb9c1111e1d2195bc27bbf34083a51a523bc91eedb3c135.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:18.098734+00:00 · HTTP 200 · SHA-256 6d6198aaffa3829940b1e80a49c9b01d30f704edc837a7f8ec4d1ac1b96b9505.

    • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
    • Other registries, unregistered studies and additional aliases remain outside this query.

    Showing 25 of 124 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. ClinicalTrials.gov NCT02020499 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    2. ClinicalTrials.gov NCT00234572 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    3. ClinicalTrials.gov NCT00543179 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    4. ClinicalTrials.gov NCT00216372 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    5. ClinicalTrials.gov NCT05048901 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    6. ClinicalTrials.gov NCT01137682 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    7. ClinicalTrials.gov NCT00729313 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    8. ClinicalTrials.gov NCT03289741 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    9. ClinicalTrials.gov NCT00353496 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    10. ClinicalTrials.gov NCT02127437 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    11. ClinicalTrials.gov NCT00630695 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    12. ClinicalTrials.gov NCT07534371 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    13. ClinicalTrials.gov NCT00774930 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    14. ClinicalTrials.gov NCT03562091 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    15. ClinicalTrials.gov NCT03792555 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    16. ClinicalTrials.gov NCT07179926 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    17. ClinicalTrials.gov NCT02685709 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    18. ClinicalTrials.gov NCT01538966 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    19. ClinicalTrials.gov NCT04198402 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    20. ClinicalTrials.gov NCT02788578 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    21. ClinicalTrials.gov NCT03112694 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    22. ClinicalTrials.gov NCT05922579 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    23. ClinicalTrials.gov NCT03083210 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    24. ClinicalTrials.gov NCT00747500 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    25. ClinicalTrials.gov NCT02288377 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    Read the full Human Evidence Review

    Supervised synthesis

    What do selected human studies report about Lanreotide?

    Manually reviewed September 15, 2026 · version 1

    Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

    Three selected reports address lanreotide in neuroendocrine tumors and acromegaly. The CLARINET extension follows participants from the original trial and is not an independent randomized experiment.123

    Bottom line from this bounded source set

    CLARINET found longer progression-free survival, without a demonstrated overall-survival or quality-of-life difference. The acromegaly study reported tumor and hormone changes but did not reject its prespecified primary null hypothesis.123

    Reviewed study record

    CLARINET: neuroendocrine tumors

    Design

    Randomized, double-blind, placebo-controlled trial over 96 weeks.1

    Population

    204 people with advanced nonfunctioning, somatostatin-receptor-positive grade 1 or 2 neuroendocrine tumors; most had stable disease before enrollment.1

    Outcomes reported

    The hazard ratio for progression or death was 0.47 (95% CI 0.30–0.73). Overall survival and quality of life did not differ significantly. Treatment-related diarrhea occurred in 26% versus 9%.1

    Limitations

    The selected tumor grades, receptor status and largely stable baseline disease limit generalization. Progression-free survival is distinct from longer overall survival.1

    Reviewed study record

    CLARINET open-label extension

    Design

    Eligible original-trial participants entered an extension in which everyone received lanreotide.2

    Population

    89 participants entered: 42 previously assigned lanreotide and 47 previously assigned placebo.2

    Outcomes reported

    The continuous-treatment group had a reported median progression-free survival of 38.5 months. Adverse-event incidence was lower during extension than during the core study.2

    Limitations

    Selective extension enrollment, crossover and absence of a concurrent placebo group prevent an independent randomized long-term comparison.2

    Reviewed study record

    PRIMARYS: acromegaly

    Design

    48-week open-label, single-arm study with centrally assessed tumor volume.3

    Population

    90 treatment-naïve people with acromegaly and growth-hormone-secreting macroadenomas entered; 64 completed.3

    Outcomes reported

    The primary analysis found at least 20% tumor-volume reduction in 62.9% of 89 participants, but the prespecified null hypothesis was not rejected. Hormonal and symptom measures also improved.3

    Limitations

    No control group, attrition and differences between primary and sensitivity analyses limit causal interpretation. No gastrointestinal-intolerance withdrawals does not mean no adverse events.3

    Reviewed source set

    1. PubMed · 25014687Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗PubMed PMID 25014687 · EFetch XML reviewed 2026-09-15 · payload SHA-256 ba560cbc89f579f1c9993801784e3b4e4720505fa3a71815cb4d17396ad5a315
      No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa1316158. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
    2. PubMed · 33052555Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. ↗PubMed PMID 33052555 · EFetch XML reviewed 2026-09-15 · payload SHA-256 965ff6216bbf51d5c511964f6dc349e1756d0980802f50665ca54b21e9fd4f86
      No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1007/s12020-020-02475-2. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
    3. PubMed · 24423301Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. ↗PubMed PMID 24423301 · EFetch XML reviewed 2026-09-15 · payload SHA-256 b36766502f349560e081866b918e66b57fcd9b2022520b5b4dffeecec32622a4
      No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2013-3318. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
    Explore status sources, recent additions, and coverage gaps

    Living status brief

    What is the current status of Lanreotide?

    U.S. label record. The cited DailyMed label identifies Lanreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

    The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

    70Dated records46PubMed records13Trial records8Regulatory records

    Evidence present

    What records are connected here?

    Evidence lanes
    4
    Source years
    15
    Drugs@FDA applications
    3

    These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

    Latest source-dated record

    What changed most recently at a cited source?

    Literature metadata · source date June 27, 2026

    PubMed record PMID 41880072↗Added to PeptideScanner August 12, 2026

    Coverage gaps

    What remains unknown or unsupported?

    All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.

    PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

    Open the complete timeline →Browse all connected recordsFollow via RSS
    Explore the Evidence Map and record counts

    Evidence Map v1

    What kinds of records connect to Lanreotide?

    Compare collection coverage →

    This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

    70Selected dated records
    71Connected citations
    15Populated source years2007–2026
    4/4Record lanes present
    Clinical trials13Open matching records →Literature metadata46Open matching records →Regulatory8Open matching records →Safety3Open matching records →

    Registered human studies

    Trial composition

    2 of 13 selected trial records include at least one phase value; 2 of 13 include a status value in the retained structured contract.

    108 public history versions connect to 12 of these trial records across 20 submitted years. Open the record-history collection →

    PhasesPhase 3 2
    Status at observationCompleted 2

    A phase value is unavailable here for 11 selected records; this is not counted as “no phase.”

    A status value is unavailable here for 11 selected records; this is not counted as a trial status.

    PubMed bibliography

    Publication composition

    22 of 46 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

    Publication typesJournal Article 17Clinical Trial 6Research Support, Non-U.S. Gov't 6Case Reports 5Letter 5Multicenter Study 5Clinical Trial, Phase II 1Clinical Trial, Phase III 1Comment 1Comparative Study 1Randomized Controlled Trial 1Review 1

    Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.

    Regulatory and publication surfaces

    What is structurally connected?

    Drugs@FDA applications
    3
    FDA Federal Register documents
    2
    DailyMed SPL versions
    3
    Canonical profile
    Published
    Profile structured data
    Published
    Linked dated records
    70

    Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

    Profile publication history and record counts

    Research hub

    Explore the Lanreotide evidence record

    Open all 70 records →
    70Dated records
    4Evidence types
    70Cited public sources
    15Source years

    Change ledger

    Recently changed for Lanreotide

    Open all 71 events →

    PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

    Record added

    ClinicalTrials.gov record NCT02493517

    PeptideScanner retained ClinicalTrials.gov record NCT02493517 at 2026-07-30T20:57:18.712Z. Its registry update date was 2019-01-29, and PeptideScanner's reviewed identity mapping was lanreotide.

    PeptideScanner change date
    September 9, 2026
    Cited source date
    January 29, 2019
    Evidence lane
    Clinical trials
    Open the cited record →
    Cited source
    Record added

    The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.

    PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    PeptideScanner change date
    September 9, 2026
    Cited source date
    February 16, 2018
    Evidence lane
    Literature metadata
    Open the cited record →
    Cited source
    Record added

    FDA enforcement report D-0290-2026

    FDA's dated enforcement report D-0290-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.

    PeptideScanner change date
    August 25, 2026
    Cited source date
    January 21, 2026
    Evidence lane
    Safety
    Open the cited record →
    Cited source

    Official-source collections

    Source records for Lanreotide

    Open the full research atlas →
    PubMed46

    22 with attributed title, venue, publication-date, and type metadata.

    Journal Article (17)Clinical Trial (6)Research Support, Non-U.S. Gov't (6)
    1. Lanreotide in endothelial corneal inflammation.Hormones (Athens, Greece) · 2025 10 10
    2. β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide.Journal of pharmaceutical sciences · 2024 11 02
    3. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.The oncologist · 2024 May 03
    Explore all selected literature →
    ClinicalTrials.gov13

    108 public history versions across these dated registry records; status labels apply only to each cited observation.

    Recruiting history (63)Active Not Recruiting history (18)Completed history (14)
    Current at observation (4)Completed at observation (9)
    Acromegaly (1)Carcinoid Syndrome (1)Phase 3 (2)Completed (2)
    Lanreotide · Drug (1)Lanreotide Acetate · Drug (1)
    1. NCT05048901Registry update April 9, 2026 · current at observation
    2. NCT02127437Registry update April 8, 2026 · completed at observation
    3. NCT06807437Registry update March 31, 2026 · current at observation
    Explore all selected trial records →Explore all public record history →
    FDA enforcement reports3

    Recall-enforcement metadata connected only through exact application numbers already mapped to this reviewed profile.

    1. D-0422-2026Class II · report date 2026-04-15
    2. D-0423-2026Class II · report date 2026-04-15
    3. D-0290-2026Class II · report date 2026-01-21
    Explore all exact FDA enforcement reports →

    Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.

    Evidence types

    Coverage by source year

    Selected records span August 30, 2007 to June 27, 2026.

    Continue exploring

    Profiles with overlapping source-year coverage

    Open the research atlas →

    These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

    Octreotide15 shared source years160 dated records · 4 evidence typesTeriparatide15 shared source years149 dated records · 3 evidence typesGlucagon13 shared source years308 dated records · 4 evidence typesLeuprolide13 shared source years215 dated records · 4 evidence types

    These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.

    Evidence summary

    What the cited records say

    The cited DailyMed label identifies Lanreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

    This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

    Cited context

    Related records

    Organizations named in cited records

    • U.S. National Library of Medicine↗

    Dated source history

    Updates connected to this profile

    Open the full cross-source timeline →

    1. Literature metadata

      PubMed record PMID 41880072↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 41880072 at 2026-07-30T16:14:14.928Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-03-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    2. Literature metadata

      PubMed record PMID 39933708↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 39933708 at 2026-07-30T16:14:10.854Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2025-02-11. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    3. Literature metadata

      PubMed record PMID 38071418↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38071418 at 2026-07-30T16:20:36.586Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-12-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    4. Literature metadata

      β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide.↗

      PubMed lists PMID 39491674 in Journal of pharmaceutical sciences as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-02 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    5. Literature metadata

      Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.↗

      PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    6. Safety

      FDA enforcement report D-0422-2026↗

      FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.↗

    7. Safety

      FDA enforcement report D-0423-2026↗

      FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations.↗

    8. Clinical trials

      ClinicalTrials.gov record NCT05048901↗

      PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide.↗

    9. Clinical trials

      ClinicalTrials.gov record NCT02127437↗

      PeptideScanner retained ClinicalTrials.gov record NCT02127437 at 2026-07-30T16:20:49.305Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was lanreotide.↗

    10. Clinical trials

      ClinicalTrials.gov record NCT06807437↗

      PeptideScanner retained ClinicalTrials.gov record NCT06807437 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was lanreotide.↗

    11. Literature metadata

      Lanreotide in endothelial corneal inflammation.↗

      PubMed lists PMID 41071230 in Hormones (Athens, Greece) as Letter, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    12. Clinical trials

      ClinicalTrials.gov record NCT03946527↗

      PeptideScanner retained ClinicalTrials.gov record NCT03946527 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was lanreotide.↗

    Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance